Back to top
more

Sorrento Therapeutics (SRNE)

(Delayed Data from OTC)

$0.02 USD

0.02
78,006

0.00 (0.00%)

Updated Apr 24, 2024 02:39 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Sorrento Therapeutics (SRNE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?

Here is how AMN Healthcare Services (AMN) and Sorrento Therapeutics (SRNE) have performed compared to their sector so far this year.

ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates

ANI (ANIP) delivered earnings and revenue surprises of 10.34% and 6.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -5.13% and 2.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.

Sorrento (SRNE) Up on Positive Result From Lung Cancer Study

Sorrento Therapeutics' (SRNE) stock rises after it announced positive results from its late-stage lung cancer study evaluating abivertinib.

Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug

Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.

Immatics (IMTX) Lags Q1 Earnings and Revenue Estimates

Immatics (IMTX) delivered earnings and revenue surprises of -18.28% and 23.88%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Evogene (EVGN) Reports Q1 Loss, Lags Revenue Estimates

Evogene (EVGN) delivered earnings and revenue surprises of -42.86% and 46.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Lags Revenue Estimates

Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of -12.50% and 5.38%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

InflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates

InflaRx N.V. (IFRX) delivered earnings and revenue surprises of 10.81% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates

IDEAYA Biosciences, Inc. (IDYA) delivered earnings and revenue surprises of -51.61% and 70.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AquaBounty Technologies, Inc. (AQB) Reports Q4 Loss, Misses Revenue Estimates

AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 0% and 56.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Zymeworks Inc. (ZYME) Reports Q4 Loss, Tops Revenue Estimates

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of 10.38% and 56.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?